Lysosomal storage diseases (LSDs) are a group of roughly 70 inherited disorders in which cells can’t properly break down certain molecules, causing waste material to build up inside compartments called lysosomes. Collectively, they affect about 1 in 5,000 to 7,500 births worldwide. Each individual disease is rare, but taken together they represent a significant category of genetic illness, most often diagnosed in infancy or childhood.
How Lysosomes Work and What Goes Wrong
Every cell in your body contains lysosomes, small structures that act as recycling centers. They use specialized enzymes to break down fats, sugars, proteins, and other large molecules into smaller pieces the cell can reuse. When one of these enzymes is missing or doesn’t work correctly, its target material accumulates inside the lysosome. Over time, swollen, clogged lysosomes interfere with normal cell function and eventually damage tissues and organs.
The specific symptoms depend on what material is piling up and where it naturally exists in the body. Fats called cerebrosides and gangliosides are abundant in the nervous system, which is why fat-storage disorders often cause severe neurological problems. Glycogen is concentrated in muscle, so Pompe disease, where glycogen breakdown fails, primarily damages skeletal and heart muscle. Sugar chains called glycosaminoglycans are found in cartilage, skin, corneas, and blood vessels, explaining the wide-ranging problems seen in mucopolysaccharidoses.
The damage isn’t limited to simple clogging. Accumulated material spills beyond the lysosome and disrupts other parts of the cell, including its outer membrane. In some diseases, the buildup triggers inflammation, activates immune cells, and promotes cell death through a cascade of toxic byproducts. In Gaucher disease, for example, fat accumulation inside immune cells called macrophages causes them to become chronically activated, driving inflammation in the liver, spleen, and bone marrow.
Inheritance Patterns
Nearly all lysosomal storage diseases are autosomal recessive, meaning a child must inherit a faulty copy of the gene from both parents to develop the condition. Parents who each carry one faulty copy typically have no symptoms themselves. Two notable exceptions are X-linked: Fabry disease and Hunter syndrome (MPS II), where the defective gene sits on the X chromosome. Males with one faulty copy develop the disease, while females who carry one copy may have milder or no symptoms.
Certain populations carry higher rates of specific LSDs. The Ashkenazi Jewish population, for instance, has a Gaucher disease frequency of about 1 in 855 births, far higher than the general population. Neuronal ceroid lipofuscinoses are more common in Finland.
Major Categories of LSDs
Lysosomal storage diseases are grouped by the type of molecule that accumulates. The three largest categories are sphingolipidoses (fat-storage disorders), mucopolysaccharidoses (sugar-chain disorders), and glycoproteinoses (protein-sugar disorders), though several important conditions fall outside these groups.
Sphingolipidoses
These involve the buildup of fatty molecules called sphingolipids. The most well-known examples include:
- Gaucher disease: The most common LSD overall. The body can’t break down a fat called glucosylceramide, which accumulates in the liver, spleen, and bone marrow. Type 1 (the most common form) spares the brain, while types 2 and 3 cause neurological decline.
- Tay-Sachs disease: A ganglioside (a type of nerve-cell fat) builds up in the brain, causing progressive neurological deterioration. The classic infantile form is fatal in early childhood.
- Fabry disease: Fats accumulate throughout the body, causing burning pain in the hands and feet, kidney damage, heart thickening, and stroke risk. Because it’s X-linked, it predominantly affects males, though female carriers can develop symptoms.
- Niemann-Pick disease: Types A and B involve a buildup of a fat called sphingomyelin in the spleen, liver, lungs, and sometimes brain. Type C is caused by defective cholesterol transport rather than a missing enzyme, and primarily affects the liver, spleen, and nervous system.
- Krabbe disease: Affects the protective covering around nerves. Toxic byproducts, rather than the stored material itself, are the main drivers of damage.
Mucopolysaccharidoses (MPS)
In these disorders, long sugar chains called glycosaminoglycans accumulate because the enzymes needed to trim them are missing. Different sugar chains concentrate in different tissues: one type is found in the cornea and cartilage, another in heart valves and blood vessels, and a third on cell surfaces throughout the lungs and blood vessels. This explains why MPS disorders tend to affect multiple organ systems.
- MPS I (Hurler/Scheie syndrome): Affects the brain, liver, spleen, heart valves, airways, and skeleton. The severe form (Hurler) causes developmental delay and regression.
- MPS II (Hunter syndrome): Similar to MPS I but X-linked. Brain involvement varies, with milder forms sparing cognition.
- MPS III (Sanfilippo syndrome): Primarily a brain disease, causing severe behavioral and psychiatric problems with relatively mild physical symptoms.
- MPS IV (Morquio syndrome): Primarily a skeletal disease, causing abnormal bone development, scoliosis, and hip problems, along with corneal clouding and hearing loss.
Other LSDs
Pompe disease doesn’t fit neatly into the categories above. It’s a disorder of glycogen (stored sugar) breakdown. Without the enzyme needed to clear glycogen from lysosomes, it accumulates in skeletal and heart muscle, causing progressive weakness and, in the infantile form, life-threatening heart enlargement. Cystinosis, another outlier, involves the accumulation of the amino acid cystine, primarily damaging the kidneys.
Signs and Symptoms
Because there are so many LSDs, there’s no single symptom profile. However, several features appear across many of these conditions and can raise suspicion, especially when they occur together in a child.
Enlargement of the liver and spleen is one of the most common findings, present in Gaucher disease, Niemann-Pick disease, and several MPS disorders. Skeletal abnormalities, including short stature, joint stiffness, and abnormal bone shapes, are hallmarks of the MPS group. Neurological decline, ranging from developmental delay in infants to loss of motor skills and cognitive function, occurs in many LSDs that affect the brain, including Tay-Sachs, Krabbe disease, and severe forms of MPS I and II.
Other recurring features include clouding of the cornea, coarsening of facial features, heart valve abnormalities, chronic respiratory problems, and muscle weakness. Many LSDs appear normal at birth, with symptoms emerging gradually over months or years as storage material accumulates. Some milder or later-onset forms may not become apparent until adulthood. Fabry disease, for instance, can present in adolescence or early adulthood with unexplained pain, kidney problems, or heart issues.
How LSDs Are Diagnosed
Diagnosis typically starts with clinical suspicion based on symptoms. Because most LSDs aren’t obvious at birth and involve multiple organ systems, there’s often a significant delay before the right tests are ordered.
The primary lab test measures the activity of the suspected missing enzyme in a blood sample. Low activity of a specific enzyme points to the corresponding disease. These enzyme assays can be performed on dried blood spots, making them practical for screening programs. The gold standard technique uses a method called tandem mass spectrometry, which can measure the activity of multiple lysosomal enzymes from a single blood spot.
Because enzyme assays can produce false positives and false negatives, results are confirmed with genetic testing that identifies the specific mutations responsible. Next-generation sequencing can analyze the relevant genes efficiently and is now the standard for molecular confirmation.
Two LSDs, Pompe disease and MPS I, have been recommended for inclusion in the U.S. newborn screening panel. Several states also screen for Fabry disease, Gaucher disease, Krabbe disease, and Niemann-Pick disease, though these haven’t yet been formally recommended at the federal level. Early detection through newborn screening is particularly valuable because treatment started before symptoms appear tends to produce much better outcomes.
Treatment Options
There is no cure for most lysosomal storage diseases, but several treatment strategies can slow progression and manage symptoms.
Enzyme Replacement Therapy
Enzyme replacement therapy (ERT) is the most established approach. It works by infusing a lab-made version of the missing enzyme directly into the bloodstream. Cells take up the infused enzyme and deliver it to their lysosomes, where it clears the accumulated material. Nine ERT products are currently approved in the U.S., covering six LSDs. Gaucher disease type 1 alone has three approved options, reflecting its status as the most common LSD. Pompe disease also has approved ERT products.
ERT requires intravenous infusions, typically every one to two weeks, for the rest of the patient’s life. It’s effective at reducing organ enlargement and improving blood counts in diseases like Gaucher, and it can stabilize muscle function in Pompe disease. A major limitation is that these infused enzymes don’t cross the blood-brain barrier well, so ERT has limited benefit for the neurological symptoms in diseases that affect the brain.
Substrate Reduction Therapy
Rather than replacing the missing enzyme, substrate reduction therapy works from the other direction: it slows the production of the material that’s accumulating. If less material is made, the small amount of residual enzyme activity a patient may have can keep pace. This approach has been used for type 1 Gaucher disease since 2003 and relies on oral medications rather than infusions.
Pharmacological Chaperone Therapy
In many LSDs, the mutated enzyme is actually produced by the cell but gets misfolded and discarded before it reaches the lysosome. Chaperone therapy uses small molecules that bind to the misshapen enzyme and help it fold correctly. Once properly folded, the enzyme can travel to the lysosome and do its job. This approach only works for patients whose mutations still allow partial enzyme function, so genetic testing is needed to determine eligibility.
Gene Therapy
Gene therapy aims to deliver a working copy of the defective gene directly into the patient’s cells, potentially providing a one-time, lasting correction. One gene therapy product, for metachromatic leukodystrophy, was approved by the European Medicines Agency in 2020. Clinical trials are actively recruiting for gene therapies targeting Fabry disease, Pompe disease, Gaucher disease, Krabbe disease, multiple MPS types, Tay-Sachs and Sandhoff diseases, and several others. Most are in early-phase trials, with metachromatic leukodystrophy and Sanfilippo syndrome type A the furthest along. Gene therapy is particularly promising for brain-affecting LSDs because it could potentially bypass the blood-brain barrier limitation that hampers enzyme replacement.
Bone marrow transplant remains an option for select conditions, particularly MPS I when performed early in life, because donor cells can take up residence throughout the body and continuously produce the missing enzyme. The procedure carries significant risks, so it’s typically reserved for severe forms where the potential benefit outweighs those risks.